In the near future, it is anticipated that specific “threshold” serum GFAP levels will be established to define “astrogliosis positivity” along the AD continuum [171], providing a standardized approach for assessing astrocyte activation in AD patients. The gene discussed is GFAP; the disease is Alzheimer disease.